Fresenius Kabi Pharmaceuticals Holding, Inc.
Fresenius Kabi Pharmaceuticals Holding, Inc., a prominent player in the global healthcare sector, is headquartered in the United States. Founded in 1996, the company has established itself as a leader in the pharmaceutical and medical device industries, focusing on lifesaving medicines and technologies. With a strong presence in North America, Europe, and Asia, Fresenius Kabi is dedicated to providing high-quality intravenous (IV) drugs, infusion therapies, and clinical nutrition products. The company is renowned for its commitment to innovation and quality, offering a diverse portfolio that includes generic injectable medications and specialty pharmaceuticals. Fresenius Kabi's unique approach to patient care and its robust supply chain have positioned it as a trusted partner in hospitals and healthcare facilities worldwide. Notable achievements include a strong market position in the parenteral nutrition segment, underscoring its role in enhancing patient outcomes across various therapeutic areas.
DitchCarbon Score
How does Fresenius Kabi Pharmaceuticals Holding, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Fresenius Kabi Pharmaceuticals Holding, Inc.'s score of 27 is lower than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Fresenius Kabi Pharmaceuticals Holding, Inc.'s reported carbon emissions
Fresenius Kabi Pharmaceuticals Holding, Inc., headquartered in the US, currently does not provide specific carbon emissions data, as there are no available figures for their emissions in kg CO2e. Consequently, details regarding their Scope 1, 2, or 3 emissions are also absent. In the absence of concrete emissions data, it is important to note that the company has not outlined any specific reduction targets or initiatives related to carbon emissions. This lack of publicly available information on their climate commitments suggests that Fresenius Kabi may still be in the early stages of developing a comprehensive sustainability strategy. As the pharmaceutical industry increasingly prioritises climate action, it is essential for companies like Fresenius Kabi to establish clear goals and transparent reporting to align with global climate standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Fresenius Kabi Pharmaceuticals Holding, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
